2.31 USD
-0.03 (-1.28%)
2.31 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to HCAT. HCAT was compared to 35 industry peers in the Health Care Technology industry. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative. HCAT is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- HCAT had positive earnings in the past year.
- In the past year HCAT has reported a negative cash flow from operations.
- In the past 5 years HCAT always reported negative net income.
- HCAT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- HCAT has a Return On Assets of -18.33%. This is comparable to the rest of the industry: HCAT outperforms 51.43% of its industry peers.
- Looking at the Return On Equity, with a value of -32.42%, HCAT is in line with its industry, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.33% | ||
| ROE | -32.42% | ||
| ROIC | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HCAT has a worse Gross Margin (47.49%) than 68.57% of its industry peers.
- HCAT's Gross Margin has declined in the last couple of years.
- HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
2. Health
2.1 Basic Checks
- HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- HCAT has more shares outstanding than it did 1 year ago.
- HCAT has more shares outstanding than it did 5 years ago.
- HCAT has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -2.22, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
- HCAT has a Altman-Z score of -2.22. This is in the lower half of the industry: HCAT underperforms 65.71% of its industry peers.
- A Debt/Equity ratio of 0.46 indicates that HCAT is not too dependend on debt financing.
- HCAT has a worse Debt to Equity ratio (0.46) than 74.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.22 |
ROIC/WACCN/A
WACC7.23%
2.3 Liquidity
- A Current Ratio of 1.88 indicates that HCAT should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.88, HCAT is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
- HCAT has a Quick Ratio of 1.88. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
- HCAT has a Quick ratio of 1.88. This is in the lower half of the industry: HCAT underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
- The earnings per share for HCAT have decreased strongly by -42.31% in the last year.
- The Revenue has been growing slightly by 4.64% in the past year.
- The Revenue has been growing by 14.63% on average over the past years. This is quite good.
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%
3.2 Future
- Based on estimates for the next years, HCAT will show a small growth in Earnings Per Share. The EPS will grow by 7.75% on average per year.
- The Revenue is expected to grow by 1.17% on average over the next years.
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y19.97%
EPS Next 5Y7.75%
Revenue Next Year1.23%
Revenue Next 2Y-0.87%
Revenue Next 3Y0.34%
Revenue Next 5Y1.17%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 15.40, the valuation of HCAT can be described as correct.
- HCAT's Price/Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 88.57% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, HCAT is valued a bit cheaper.
- A Price/Forward Earnings ratio of 6.28 indicates a rather cheap valuation of HCAT.
- Based on the Price/Forward Earnings ratio, HCAT is valued cheaper than 97.14% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. HCAT is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.4 | ||
| Fwd PE | 6.28 |
4.2 Price Multiples
- HCAT's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 95.68 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as HCAT's earnings are expected to grow with 19.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.66%
EPS Next 3Y19.97%
5. Dividend
5.1 Amount
- No dividends for HCAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.31
-0.03 (-1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-05 2026-05-05
Inst Owners79.29%
Inst Owner Change0.69%
Ins Owners4.64%
Ins Owner Change6.2%
Market Cap163.39M
Revenue(TTM)316.06M
Net Income(TTM)-107.62M
Analysts72.94
Price Target3.95 (71%)
Short Float %7.74%
Short Ratio7.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-0.72%
Max EPS beat(2)15.68%
EPS beat(4)2
Avg EPS beat(4)89.55%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)5
Avg EPS beat(8)389.25%
EPS beat(12)9
Avg EPS beat(12)423.71%
EPS beat(16)13
Avg EPS beat(16)328.14%
Revenue beat(2)0
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-1.41%
Revenue beat(4)0
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-1.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.46%
Revenue beat(12)2
Avg Revenue beat(12)-1.03%
Revenue beat(16)5
Avg Revenue beat(16)-0.71%
PT rev (1m)-1.76%
PT rev (3m)-14.94%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-15.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.82%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)-2.99%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-1.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.4 | ||
| Fwd PE | 6.28 | ||
| P/S | 0.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 95.68 |
EPS(TTM)0.15
EY6.49%
EPS(NY)0.37
Fwd EY15.94%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS4.47
BVpS4.69
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.33% | ||
| ROE | -32.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.49% | ||
| FCFM | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 83.43 | ||
| Cap/Depr | 43.42% | ||
| Cap/Sales | 6.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | -2.22 |
F-Score5
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y19.97%
EPS Next 5Y7.75%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%
Revenue Next Year1.23%
Revenue Next 2Y-0.87%
Revenue Next 3Y0.34%
Revenue Next 5Y1.17%
EBIT growth 1Y28.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.38%
EBIT Next 3Y42.06%
EBIT Next 5Y29.55%
FCF growth 1Y24.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A
HEALTH CATALYST INC / HCAT FAQ
What is the fundamental rating for HCAT stock?
ChartMill assigns a fundamental rating of 2 / 10 to HCAT.
Can you provide the valuation status for HEALTH CATALYST INC?
ChartMill assigns a valuation rating of 5 / 10 to HEALTH CATALYST INC (HCAT). This can be considered as Fairly Valued.
Can you provide the profitability details for HEALTH CATALYST INC?
HEALTH CATALYST INC (HCAT) has a profitability rating of 1 / 10.
What is the valuation of HEALTH CATALYST INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HEALTH CATALYST INC (HCAT) is 15.4 and the Price/Book (PB) ratio is 0.49.
Can you provide the expected EPS growth for HCAT stock?
The Earnings per Share (EPS) of HEALTH CATALYST INC (HCAT) is expected to decline by -25.32% in the next year.